Loading clinical trials...

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

NCT00514865•Ono Pharma USA Inc

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed with recurrent major depressive disorder

Exclusion Criteria

•Patients with treatment resistance for depression
•History of alcohol abuse/dependence, substance abuse/dependence within 6 months
•Has clinically significant unstable medical condition
•Has significant risk of suicide

Locations (1)

Ono Pharma Investigtional Site

Atlanta, Georgia, United States

Key Dates

Start Date

June 13, 2007

Primary Completion Date

April 1, 2008

Completion Date

June 1, 2008

Last Updated

November 28, 2023

Enrollment

278

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

ONO-2333Ms Experimental 2

DRUG

Placebo

DRUG

ONO-2333Ms Experimental 1

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults